Carmelo Lafuente-Lafuente

Summary

Country: France

Publications

  1. doi request reprint [Anticoagulation of older patients: what is new?]
    Carmelo Lafuente-Lafuente
    Groupe hospitalier Pitié Salpêtrière Charles Foix AP HP, site Charles Foix, pôle de gériatrie Paris Val de Marne, 94205 Ivry sur Seine, France
    Presse Med 42:187-96. 2013
  2. doi request reprint [Clinical pharmacology and aging]
    Carmelo Lafuente-Lafuente
    AP HP, Groupe hospitalier Pitié Salpêtrière Charles Foix, pôle de gériatrie Paris Val de Marne, site Charles Foix, 94205 Ivry sur Seine, France
    Presse Med 42:171-80. 2013

Detail Information

Publications2

  1. doi request reprint [Anticoagulation of older patients: what is new?]
    Carmelo Lafuente-Lafuente
    Groupe hospitalier Pitié Salpêtrière Charles Foix AP HP, site Charles Foix, pôle de gériatrie Paris Val de Marne, 94205 Ivry sur Seine, France
    Presse Med 42:187-96. 2013
    ..NOA also have other unresolved problems: drug interactions are still possible, specific coagulation test to assess them must be developed, and no specific antidote is currently available in case of hemorrhagic complication...
  2. doi request reprint [Clinical pharmacology and aging]
    Carmelo Lafuente-Lafuente
    AP HP, Groupe hospitalier Pitié Salpêtrière Charles Foix, pôle de gériatrie Paris Val de Marne, site Charles Foix, 94205 Ivry sur Seine, France
    Presse Med 42:171-80. 2013
    ..Finally, some drugs should be avoided in older patients because of a bad effectiveness/tolerance ratio compared to alternatives...